NCT05839470View on ClinicalTrials.gov

Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 19, 2023

Primary Completion Date

March 1, 2024

Study Completion Date

March 1, 2025

Conditions
Colorectal Cancer
Interventions
DRUG

cadonilimab

Cadonilimab (6mg/kg, iv, Q2W, Day1)

DRUG

irinotecan

irinotecan\* 165 mg/m² iv continue for 1.5 hours, D1

DRUG

Oxaliplatin

oxaliplatin 85 mg/m² iv continue for 2 hours,

DRUG

leucovorin or levoleucovorin

leucovorin 400 or levoleucovorin 200 mg/m² iv continue for 2 hours

DRUG

5-FU

5-FU 2400 mg/m² cont. inf. 46h

Trial Locations (1)

Unknown

RECRUITING

Fujian Cancer Hospital, Fuzhou

All Listed Sponsors
lead

Fujian Cancer Hospital

OTHER_GOV